Bridging the critical gap between unstandardized empirical phytochemistry and the rigorous demands of evidence-based global pharmacology.
Secondary metabolites in plants (alkaloids, polyphenols, ginsenosides, and polysaccharides) fluctuate dramatically based on geoclimatic altitude, seasonal precipitation, soil microbiome, and post-harvest drying. Manufacturers without rigorous ODM contract research face batch failures, regulatory rejections, and efficacy divergence across global retail channels.
Regulatory bodies including the US FDA (NDI, GRAS dossiers), European EMA (Herbal Drug Monographs), and China NMPA have raised the scientific bar. Simple solvent extraction without fingerprint chromatograms, genotoxicity profiles (Ames, Micronucleus), and validated MOA (Mechanisms of Action) cannot survive current New Dietary Ingredient or Botanical Drug scrutiny.
More than 70% of novel active discoveries fail during pilot industrialization due to thermal degradation, phase precipitation, solvent residue cross-contamination, or crystalline polymorphism instability. Unifying research contract laboratories (CRO) with contract development and manufacturing (CDMO) is the only proven method to preserve chemical integrity.
Backed by 14+ years of specialized contract research for China’s premier pharmaceutical conglomerates and TCM university hospitals.
MedGence (Yineng Pharma) operates an end-to-end continuum ensuring seamless transition from biological target identification to commercial batch synthesis.
High-throughput screening across complex matrices (polyphenols, polysaccharides, alkaloids, and terpenoids) leveraging extensive phytochemical databases to pinpoint the exact molecule responsible for target therapeutic outcomes.
View service details →
Geographical sourcing optimization. We systematically evaluate botanical content across distinct terroirs, harvesting windows, and plant anatomical fractions (rhizome vs. aerial leaf) to establish maximum yields and cost barriers.
View service details →
Development and validation of robust analytical methods using HPTLC, HPLC-DAD, LC-MS/MS, GC-FID, and chromatographic fingerprinting to verify chemical purity, stability, and batch-to-batch chemical equivalence.
View service details →
Engineering pilot-scale extraction, macro-porous resin purification, membrane separation, and crystallization protocols that maximize target recovery while systematically eliminating toxic residual solvents and heavy metals.
View service details →
Overcoming botanical formulation hurdles including hygroscopicity, poor aqueous solubility, and low bioavailability through microencapsulation, spray-granulation, and lipid-based drug delivery systems (SEDDS).
View service details →
Rigorous non-clinical toxicology dossiers. Executing OECD-compliant acute oral toxicity, 90-day sub-chronic repeat toxicity, bacterial reverse mutation (Ames test), and chromosomal aberration assays required for regulatory clearance.
View service details →
Mechanistic validation at the receptor, cellular, and enzymic level. Quantitative assessment of antioxidant capacity (ORAC), anti-inflammatory cytokine expression (TNF-α, IL-6), tyrosinase inhibition, and metabolic pathway modulation.
View service details →
Validated disease models in rodents and non-rodents for metabolic syndrome, neuroprotection, immune stimulation, and hepatoprotection. Providing unequivocal physiological proof-of-concept before human trial commitments.
View service details →
Full GCP clinical operations: randomized, double-blind, placebo-controlled human trials for dietary supplement claim substantiation, as well as formal Phase I pharmacokinetic/safety through Phase IV post-market drug surveillance.
View service details →
Deciphering multi-herb synergies through network pharmacology. We optimize complex TCM polyherbal prescriptions into reproducible, standardized fixed-dose combinations that comply with modern pharmacology conventions.
View service details →
Supplying commercial quantities of validated active molecules as high-potency standardized powders, concentrated liquid extracts, semi-solid oleoresins, or supercritical volatile oils, packaged under nitrogen in GMP cleanrooms.
Request API Specifications →
Turnkey contract commercialization spanning high-speed encapsulation (hard gelatin and vegetarian HPMC), softgel encapsulation, multi-layer tableting, sterile oral liquids, and soluble effervescent sachet stick packs.
Request Finished Product Specs →Every contract research milestone delivers audit-ready scientific documentation, ensuring procurement heads and R&D directors maintain complete risk visibility.
Phytochemical literature mining, ethnobotanical evaluation, target bioactivity matching, and multi-origin botanical profiling.
Deliverable: Target Molecule & Sourcing MonographMethod validation according to ICH Q2(R1) guidelines. Chromatographic fingerprinting and heavy metal/pesticide limits.
Deliverable: Validated QC Assay Protocols & COAFractional optimization, critical process parameters (CPP) definition, yield kinetics, and solvent recycling modeling.
Deliverable: Pilot Batch Manufacturing Master RecordGLP-compliant toxicology testing (LD50, Ames), target cellular in vitro assays, and rodent pharmacokinetics.
Deliverable: Preclinical Safety & Efficacy DossierInstitutional Review Board (IRB) approved human clinical trials measuring primary and secondary biological endpoints.
Deliverable: GCP-Compliant Clinical Study Report (CSR)Scale-up in automated cleanroom suites. Batch release testing, stability storage testing (ICH conditions), and secured delivery.
Deliverable: Commercial Batches with Full DossierNavigating regional compliance frameworks is woven into every stage of our contract research, drastically shortening time-to-market across target territories.
In the United States, introducing a new dietary ingredient demands compliance with 21 CFR 190.6 (NDI Notification) or achieving Self-Affirmed / FDA-notified GRAS (Generally Recognized as Safe) status. MedGence researchers compile historical intake evidence, 90-day oral toxicity data, in vitro genotoxicity studies, and production manufacturing specs required by independent expert safety panels.
EU regulations classify non-consumed botanical fractions as Novel Foods (Regulation (EU) 2015/2283), requiring molecular characterization, stability profiles, and toxicological safety tiers. For traditional medicines, our research supports the Committee on Herbal Medicinal Products (HMPC) standards, providing documented traditional use records and validated chemical monographs.
Capitalizing on our domestic headquarters in Changsha, Hunan, we execute turnkey registrations for NMPA Hospital Preparations and New Botanical Drug Class 1.1 / 1.2 submissions. Furthermore, for cosmetic innovators, we manage the intricate NMPA New Cosmetic Ingredient Notification System, including safety evaluations and the mandatory 3-year safety monitoring lifecycle.
We supply chemical dossiers tailored to the Australian Therapeutic Goods Administration (TGA) for Listed and Registered Complementary Medicines. All extraction protocols eliminate prohibited processing aids, enabling frictionless certification for MUI Halal, cKOSHER, Non-GMO Project, and ISO 22000 / FSSC 22000 food safety standards.
Custom ODM contract research empowers diverse product categories by replacing generic raw commodities with proprietary, defensible active ingredient platforms.
Standardized bioactive compounds engineered for clean-label capsules, tablets, and gummies. Backed by randomized controlled trial (RCT) human data to substantiate health claims for cognitive performance, glycemic regulation, joint mobility, and sleep architecture.
Advancing isolated phytochemical single-molecules and enriched fractions through preclinical pharmacology, PK/PD metabolic profiling, and Phase I–IV clinical studies in pursuit of New Drug Applications (NDA) for cardiovascular, oncological, or antiviral indications.
High-purity botanical actives optimized for transdermal penetration and stability. Proven clinical efficacy in matrix metalloproteinase (MMP) inhibition, cellular renewal, skin barrier repair, and melanogenesis suppression without cytotoxic sensitization.
Water-soluble, clear-dissolving, taste-masked botanical extracts tailored for functional drinks, shot formulations, and Foods for Special Medical Purpose (FSMP) that withstand HTST/UHT thermal processing without precipitation or loss of potency.
How computational biology, multi-omics, and green manufacturing technologies are reshaping the economics of natural active ingredient contract research.
By integrating generative machine learning models and molecular docking algorithms, we simulate how thousands of unstudied phytochemicals bind with human enzyme and receptor pockets (e.g., AMPK, Sirtuin, GABA-A). This compresses initial screening cycles from 18 months down to several weeks.
Phasing out toxic petroleum-derived solvents (hexane, dichloromethane) in favor of Supercritical Fluid Extraction (SFE-CO2) with eco-friendly co-solvents (water/ethanol). This guarantees zero toxic chemical residues while preserving fragile thermosensitive polyphenol complexes.
Combining transcriptomics, proteomics, and metabolomics to map the complete biological cascade induced by botanical multi-component cocktails. This eliminates the "black box" stigma of traditional botanicals, presenting clear mechanistic evidence to worldwide regulatory bodies.
Our contract research directly powers the formulations, hospital preparations, and commercial lines of leading healthcare institutions.
Critical commercial, technical, and intellectual property queries addressed for pharmaceutical procurement officers, regulatory counsel, and venture R&D heads.